Skip to main content
. 2025 Aug 25;17:21. doi: 10.1186/s41479-025-00173-z

Table 4.

Outcomes, length of stay and therapeutics (n = 162)

Variables Median or percentage
SOFA at 48 h 5 [3–8]
No Ventilation 33 (20.4)
Non-invasive ventilation 9 (5.6)
Median days 4 [3–7]
High-flow nasal oxygen therapy 21 (13)
Median days 4 [2–5]
NIV and HFOT 4 (2.5)
Median days 1.5 [1-2.5]
Invasive ventilation 95 (58.6)
Median days 10 [6–17]
Invasive ventilation at admission (n = 95) 79 (83.2)
Invasive ventilation after 24 h (n = 95) 16 (16.8)
Median days ventilation/admission 2.5 [2-3.5]
Acute respiratory distress syndrome 73 (45.1)
Paralysis for ARDS (n = 73) 65 (85)
Prone position for ARDS (n = 73) 39 (53.4)
Extracorporeal membrane oxygenation 8 (4.9)
Vasopressors 84 (51.9)
Renal replacement therapy 27 (16.7)
Median days 6.5 [3–12]
Combination therapy antibiotics 128 (79.1)
Median days 10 [7–15]
Mono-therapy antibiotic 33 (20.4)
Antibiotherapy median days 18 [14–21]
No antibiotics 1 (0.6)
No antibiotics at ICU admission 6
Median days antibiotic/hospitalization 0 [0–1]
Median days antibiotic/ICU 0 [0–0]
No antibiotics at ICU admission 6 (3.7)
Median days diagnosis/hospitalization 1 [0–2]
Median days of ICU 11 [5–19]
Median days of hospitalization 17 [10–29]
28-day mortality 19 (11.7)
ICU mortality 21 (13)
Hospital mortality 22 (13.6)

Data are presented as No (%) or median (Q1-Q3) unless otherwise indicate

NIV a non-invasive ventilation

HFOT high-flow nasal oxygen therapy

ARDS acute respiratory distress syndrome

Extracorporeal membrane oxygenation corresponds to veno-venous extracorporeal membrane oxygenation